INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Bellerophon Therapeutics, Inc. And Advises Investors With Losses To Contact The Firm

Goldberg Law PC announces that it is investigating Bellerophon Therapeutics, Inc. ("Bellerophon" or the "Company") (Nasdaq: BLPH) concerning possible violations of federal securities laws.

If you purchased or otherwise acquired Bellerophon shares and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm's website at, or by email at

The investigation concerns whether Bellerophon and certain of its officers and/or directors violated federal securities laws. On February 13, 2015 the Company had its Initial Public Offering and sold 13 million shares. Since the IPO, Bellerophon shares have fallen drastically in value, following the Company's report about poor operating results and executive changes.

If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at, or email us at

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on

Copyright Business Wire 2010